The Bishop of St Albans received the following written answers on 20th September 2023:
The Lord Bishop of St Albans asked His Majesty’s Government what service the NHS provides for people with fibrodysplasia ossificans progressiva.
Lord Markham (Con, Department of Health & Social Care): While there is no specific prescribed service for fibrodysplasia ossificans progressiva (FOP), children with the condition are cared for by National Health Service paediatric rheumatologists and/or geneticists with input from other clinicians as required. For patients with rare diseases such as FOP, expert centres provide clinical guidance, support and advice to patients, their families, and carers.
The Lord Bishop of St Albans asked His Majesty’s Government, further to the Written Answer by Lord Markham on 7 September (HL9841), whether they have any plans to discuss Vorasidenib with Servier Laboratories.
Lord Markham: The Medicines and Healthcare products Regulatory Agency (MHRA) has not granted a marketing authorisation for Vorasidenib, however should an application be received from Servier Laboratories, the MHRA has licensing pathways available, with the aim of ensuring the products can be made available for patients in the United Kingdom in the shortest time possible and to support and protect public health. While the MHRA will assess any submitted applications and is willing to facilitate the appropriate regulatory processes, the agency cannot actively seek these applications and as such there are currently no plans to discuss Vorasidenib with Servier Laboratories.
The Church of England in Parliament 
You must be logged in to post a comment.